Revenio Group: Targeting 5%-10% annual growth and 25% EBITDA margin by 2029 through expanded eye health solutions
The company is shifting from vision care to connected eye health, expanding its addressable market and product portfolio through the Visionix acquisition. Strategic priorities include advancing clinical confidence, scaling operations, and leveraging synergies for 5%-10% annual growth and a 25% EBIT…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.